Elevation Oncology, Inc. (ELEV)
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
ELEV Insider Trading Activity
ELEV Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
About Elevation Oncology, Inc.
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Insider Activity of Elevation Oncology, Inc.
Over the last 12 months, insiders at Elevation Oncology, Inc. have bought $0 and sold $0 worth of Elevation Oncology, Inc. stock.
On average, over the past 5 years, insiders at Elevation Oncology, Inc. have bought $26M and sold $2.9M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 187,500 shares for transaction amount of $3M was made by Aisling Capital IV, LP (10 percent owner) on 2021‑06‑29.
List of Insider Buy and Sell Transactions, Elevation Oncology, Inc.
| 2022-05-25 | Sale | Royston Aaron | 702,737 3.1622% | $4.12 | $2.9M | -69.80% | ||
| 2021-06-29 | Aisling Capital IV, LP | 10 percent owner | 187,500 22.5074% | $16.00 | $3M | -56.00% | ||
| 2021-06-29 | venBio Global Strategic Fund III, L.P. | 10 percent owner | 625,000 75.0247% | $16.00 | $10M | -56.00% | ||
| 2021-06-29 | Qiming U.S. Healthcare Fund II, L.P. | 10 percent owner | 312,500 37.5123% | $16.00 | $5M | -56.00% | ||
| 2021-06-29 | Vertex Global HC Fund II Pte. Ltd. | 10 percent owner | 250,000 30.0099% | $16.00 | $4M | -56.00% | ||
| 2021-06-29 | Cormorant Asset Management, LP | 250,000 30.0099% | $16.00 | $4M | -56.00% |
Insider Historical Profitability
| Aisling Capital IV, LP | 10 percent owner | 2834910 4.7874% | $1.37M | 1 | 0 | <0.0001% |
| venBio Global Strategic Fund III, L.P. | 10 percent owner | 2608167 4.4045% | $1.26M | 1 | 0 | <0.0001% |
| Qiming U.S. Healthcare Fund II, L.P. | 10 percent owner | 2370142 4.0025% | $1.14M | 1 | 0 | <0.0001% |
| Vertex Global HC Fund II Pte. Ltd. | 10 percent owner | 2307642 3.897% | $1.11M | 1 | 0 | <0.0001% |
| Cormorant Asset Management, LP | 2233168 3.7712% | $1.08M | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$14,315,062 | 61 | -6.21% | $30.86M | |
$53,490,060 | 55 | 19.35% | $32.57M | |
$94,084,626 | 29 | -21.08% | $27.92M | |
$1,295,471 | 17 | 21.79% | $24.68M | |
$17,594,514 | 16 | -20.37% | $32.66M |
ELEV Institutional Investors: Active Positions
| Increased Positions | 39 | +58.21% | 2M | +4.68% |
| Decreased Positions | 24 | -35.82% | 9M | -18.78% |
| New Positions | 14 | New | 1M | New |
| Sold Out Positions | 11 | Sold Out | 4M | Sold Out |
| Total Postitions | 82 | +22.39% | 40M | -14.09% |
ELEV Ownership Change vs Market
Institutional Investor Ownership
| Frazier Life Sciences Management, L.P. | $3,195.00 | 10.16% | 5.99M | 0 | 0% | 2024-12-31 |
| Tang Capital Management Llc | $2,537.00 | 8.07% | 4.76M | 0 | 0% | 2024-12-31 |
| Farallon Capital Management Llc | $1,880.00 | 5.98% | 3.53M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $1,686.00 | 5.36% | 3.16M | +258,009 | +8.88% | 2024-12-31 |
| Bvf Inc/Il | $1,581.00 | 5.03% | 2.97M | 0 | 0% | 2024-12-31 |
| Aisling Capital Management Lp | $1,511.00 | 4.81% | 2.83M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $1,391.00 | 4.42% | 2.61M | -461,535 | -15.03% | 2024-12-31 |
| Goldman Sachs Group Inc | $880.00 | 2.8% | 1.65M | -2M | -58.59% | 2024-12-31 |
| Renaissance Technologies Llc | $855.00 | 2.72% | 1.6M | -182,673 | -10.23% | 2024-12-31 |
| Geode Capital Management, Llc | $617.00 | 1.96% | 1.16M | +47,487 | +4.28% | 2024-12-31 |